Please assess the completion status of the following clinical trial:

Trial Title: St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following:~  * Noninvasive ductal carcinoma in situ~ * Localized breast cancer~    * Stage 0-IIIB disease~ * Locally recurrent breast cancer that is post-treatment AND disease-free for ≥ 2 years~* Experiencing ≥ 3 hot flashes per day (≥ 21 per week), defined by sweating, flushing, sensation of warmth, night sweats, and/or rapid heart beat of sufficient severity that the patient desires therapeutic intervention~* Normal mammogram within the past 10 months~* Hormone receptor status:~  * Not specified~INCLUSION CRITERIA:~Age~* 18 and over~Sex~* Female~Menopausal status~* Post-menopausal (i.e., no menstrual periods ≥ 12 months or surgical menopause)~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin \< 2 mg/dL~* SGOT ≤ 2 times normal~Renal~* Not specified~EXCLUSION CRITERIA:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No history of intolerance to St. John's wort~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No concurrent cytotoxic chemotherapy~Endocrine therapy~* No concurrent selective estrogen-receptor modulators or aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane) allowed~  * Concurrent tamoxifen allowed~* No concurrent estrogen, progestational agents, or androgens for the alleviation of hot flashes~* No concurrent corticosteroids~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* More than 14 days since prior Hypericum perforatum (St. John's wort), monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (e.g., sertraline, paroxetine, or fluoxetine) or selective norepinephrine reuptake inhibitors (e.g., venlafaxine)~* No concurrent use of any of the following:~  * Antidepressants~ * Theophylline~ * Warfarin, unless for central line prophylaxis~ * Protease inhibitors for AIDS~ * Digoxin~ * Cyclosporine~ * Benzodiazepines (e.g., diazepam or alprazolam)~ * Calcium-channel blockers (e.g., diltiazem or nifedipine)~ * Coenzyme A reductase inhibitors for serum cholesterol reduction~ * Macrolide antibiotics (e.g., azithromycin, erythromycin, or clarithromycin)~ * Griseofulvin~ * Phenobarbital~ * Phenytoin~ * Rifampin~ * Rifabutin~ * Grapefruit juice~ * Other naturopathic or herbal products~ * Ketoconazole~ * Fluconazole~ * Itraconazole~ * Rifabutin~* No other concurrent medications for the alleviation of hot flashes (e.g., clonidine or bellamine)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- St. John's Wort (Type: EXPERIMENTAL): Patient given one 300mg St. John's Wort tablet three times per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues